Literature DB >> 24764126

Overexpression of cyclin dependent kinase inhibitor P27/Kip1 increases oligodendrocyte differentiation from induced pluripotent stem cells.

Shinpei Tamaki1, Yasuhito Tokumoto.   

Abstract

Cell transplantation therapy with oligodendrocyte precursor cells (OPCs) is a promising and effective treatment for diseases involving demyelination in the central nervous system (CNS). In previous studies, we succeeded in producing O4(+) oligodendrocytes (OLs) from mouse- and human-induced pluripotent stem cells (iPSCs) in vitro; however, the efficiency of differentiation into OLs was lower for iPSCs than that for embryonic stem cells (ESCs). To clarify the cause of this difference, we compared the expression of proteins that contribute to OL differentiation in mouse iPSC-derived cells and in mouse ESC-derived cells. The results showed that the expression levels of cyclin dependent kinase inhibitor P27/Kip1, mitogen-activated protein kinase (MAPK) JNK3, and transcription factor Mash1 were lower in iPSC-derived cells. In contrast, the expression levels of MAPK P38α, P38γ, and thyroid hormone receptor β1 were higher in iPSC-derived cells. We attempted to compensate for the expression changes in P27/Kip1 protein and Mash1 protein in iPSC-derived cells through retrovirus vector-mediated gene expression. Although the overexpression of Mash1 had no effect, the overexpression of P27/Kip1 increased the differentiation efficiency of iPSC-derived cells into O4(+) OLs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24764126     DOI: 10.1007/s11626-014-9753-2

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  29 in total

1.  Lack of replicative senescence in cultured rat oligodendrocyte precursor cells.

Authors:  D G Tang; Y M Tokumoto; J A Apperly; A C Lloyd; M C Raff
Journal:  Science       Date:  2001-01-18       Impact factor: 47.728

2.  Comparison of efficiency of terminal differentiation of oligodendrocytes from induced pluripotent stem cells versus embryonic stem cells in vitro.

Authors:  Yasuhito Tokumoto; Shinichiro Ogawa; Teruyuki Nagamune; Jun Miyake
Journal:  J Biosci Bioeng       Date:  2009-12-14       Impact factor: 2.894

Review 3.  The life, death, and replacement of oligodendrocytes in the adult CNS.

Authors:  Dana M McTigue; Richa B Tripathi
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 4.  Intracellular developmental timers.

Authors:  M Raff
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2007

5.  Induction of oligodendrocyte differentiation from adult human fibroblast-derived induced pluripotent stem cells.

Authors:  Shin-ichiro Ogawa; Yasuhito Tokumoto; Jun Miyake; Teruyuki Nagamune
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-06-22       Impact factor: 2.416

Review 6.  The use of induced pluripotent stem cells in drug development.

Authors:  H Inoue; S Yamanaka
Journal:  Clin Pharmacol Ther       Date:  2011-03-23       Impact factor: 6.875

7.  Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein.

Authors:  Y M Tokumoto; D G Tang; M C Raff
Journal:  EMBO J       Date:  2001-09-17       Impact factor: 11.598

8.  Generation of germline-competent induced pluripotent stem cells.

Authors:  Keisuke Okita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

9.  In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.

Authors:  Marius Wernig; Alexander Meissner; Ruth Foreman; Tobias Brambrink; Manching Ku; Konrad Hochedlinger; Bradley E Bernstein; Rudolf Jaenisch
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

Review 10.  Induced pluripotent stem cells: current progress and potential for regenerative medicine.

Authors:  Giovanni Amabile; Alexander Meissner
Journal:  Trends Mol Med       Date:  2009-01-21       Impact factor: 11.951

View more
  5 in total

Review 1.  Induced Stem Cells as a Novel Multiple Sclerosis Therapy.

Authors:  Chong Xie; Yan-Qun Liu; Yang-Tai Guan; Guang-Xian Zhang
Journal:  Curr Stem Cell Res Ther       Date:  2016       Impact factor: 3.828

Review 2.  Intracellular Protein Shuttling: A Mechanism Relevant for Myelin Repair in Multiple Sclerosis?

Authors:  Peter Göttle; Patrick Küry
Journal:  Int J Mol Sci       Date:  2015-07-03       Impact factor: 5.923

3.  Purinergic Receptor Expression and Potential Association with Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cell Development.

Authors:  Shirin Kashfi; Maryam Peymani; Kamran Ghaedi; Hossein Baharvand; Mohammad Hossein Nasr-Esfahani; Mohammad Javan
Journal:  Cell J       Date:  2017-08-19       Impact factor: 2.479

4.  Transplanted miR-219-overexpressing oligodendrocyte precursor cells promoted remyelination and improved functional recovery in a chronic demyelinated model.

Authors:  Hong-Bin Fan; Li-Xia Chen; Xue-Bin Qu; Chuan-Lu Ren; Xiu-Xiang Wu; Fu-Xing Dong; Bao-Le Zhang; Dian-Shuai Gao; Rui-Qin Yao
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

5.  Mutant BCL11B in a Patient With a Neurodevelopmental Disorder and T-Cell Abnormalities.

Authors:  Sai Yang; Qingyun Kang; Yanqi Hou; Lili Wang; Liping Li; Shulei Liu; Hongmei Liao; Zhenhua Cao; Liming Yang; Zhenghui Xiao
Journal:  Front Pediatr       Date:  2020-10-19       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.